Welcome to our dedicated page for Pharvaris N.V. SEC filings (Ticker: PHVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pharvaris N.V. filings document foreign private issuer disclosures for a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists. Form 6-K reports furnish financial results, business updates, investor presentations, clinical-study updates, annual general meeting voting results and materials incorporated by reference into Form F-3 and Form S-8 registration statements.
The filing record also covers capital-structure activity involving ordinary shares and pre-funded warrants, registration rights agreements, underwriting documents, share-based compensation and governance matters. These disclosures frame Pharvaris' development-stage operating expenses, financing activity, shareholder approvals and formal reporting obligations as a Nasdaq-listed foreign private issuer.
On July 13, 2026, Pharvaris N.V. Chief Executive Officer Berndt Modig executed an open-market sale of 2,292 shares of common stock at a weighted average price of $34.9714, pursuant to a scheduled Rule 10b5-1 trading plan. Following this sale, he holds 132,917 shares directly and 950,000 shares indirectly through Schoodic Management BV.
Pharvaris N.V. Chief Medical Officer Lu Peng reported two tax-withholding dispositions tied to vesting of restricted stock units. The issuer withheld 117 and 109 common shares, totaling 226 shares, at $35.07 per share to cover tax obligations, leaving Peng with 65,405 shares held directly.
PHVS shareholder Berndt B.A.E. Modig has filed to sell up to 2,292 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ, with an indicated aggregate value of $80,380.44 for a planned trade date of July 13, 2026. The shares relate to Restricted Stock Units dated July 11, 2026 and the filing also lists prior Rule 10b5-1 sales in April, May, and June 2026 of about 2,291–2,292 shares each, with aggregate values between $65,558.53 and $71,172.89.
Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported open-market sales of company common stock under a pre-arranged Rule 10b5-1 trading plan. He sold 6,888 shares on June 29, 2026 at a weighted average price of $35.0533 per share and 30,712 shares on June 30, 2026 at a weighted average price of $35.4926 per share.
Following these transactions, he directly holds 315,167 Pharvaris common shares. Footnotes state that both sales were executed through multiple trades within daily price ranges of $35.00–$35.10 and $35.00–$35.90, respectively, and were carried out pursuant to his Rule 10b5-1 trading plan.
Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a mix of stock option exercises and share sales in Pharvaris common stock. She exercised options to acquire 37,572 shares at strike prices of $8.05 and $2.59 per share, then sold 76,172 shares in open-market transactions at weighted average prices around $35 per share. The filing states these were scheduled transactions under a Rule 10b5-1 trading plan and involved cashless exercise of options. After the transactions, she holds 58,750 shares directly and 93,969 shares indirectly through GrayMatters Consulting B.V., an entity she controls.
PHVS reports insider sales under pre-arranged 10b5-1 plans by Anne Simonne J. Lesage and Graymatters Consulting B.V. The excerpt lists multiple completed 10b5-1 sales of Common stock on specific dates in 2026, including 21,700 shares on 04/30/2026 and 8,300 shares on 06/29/2026 by the named parties.
The filing records each sale with the trade date and gross proceeds shown in dollars; cash-flow treatment and aggregate registered offering details are not included in the provided excerpt.
PHVS notice of proposed sales under Rule 144 and 10b5-1 plans by insiders and affiliated holders. The excerpt lists multiple 10b5-1 sales and an exercise of stock options that generated sales on and around 04/22/2026 through 06/30/2026. Named sellers include Anne Simonne J. Lesage and Graymatters Consulting B.V. with individual trade lines such as 21,700 shares on 04/30/2026 and 8,300 shares on 06/29/2026. The transactions are reported as brokered sales with cash consideration.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice relating to proposed sales of Common shares linked to Founders Shares. The filing also lists recent 10b5-1 sales by Hans H. Schikan, including 6,888 shares on 06/29/2026 for $241,447.13 and 29,070 shares on 04/30/2026 for $881,378.75.
Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a scheduled option exercise and share sale on June 25, 2026 under a Rule 10b5-1 trading plan.
She sold 2,300 Pharvaris common shares indirectly through GrayMatters Consulting B.V. and 2,300 shares directly in open‑market transactions at weighted average prices of $35.1242 and $35.1194 per share. The sales were linked to a cashless exercise of stock options for 900 shares at $8.05 and 1,400 shares at $2.59 per share. Following these transactions, Lesage holds 56,450 common shares directly and 131,669 shares indirectly through GrayMatters, while option grants continue to vest over time as disclosed.
Pharvaris N.V. director Johannes Gerardus Christiaan Petrus Schikan reported an open-market sale of 2,400 shares of common stock. The shares were sold at a weighted average price of $35.1041 per share under a pre-arranged Rule 10b5-1 trading plan, with individual trade prices ranging from $35.00 to $35.30. After this transaction, Schikan directly holds 352,767 shares of Pharvaris common stock.